240 related articles for article (PubMed ID: 27380347)
1. Tumor Screening and DNA Testing in the Diagnosis of Lynch Syndrome.
Usha L; Dewdney SB; Buckingham LE
JAMA; 2016 Jul; 316(1):93-4. PubMed ID: 27380347
[No Abstract] [Full Text] [Related]
2. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
[TBL] [Abstract][Full Text] [Related]
3. Role of endometrial cancer abnormal MMR protein in screening Lynch-syndrome families.
Long Q; Peng Y; Tang Z; Wu C
Int J Clin Exp Pathol; 2014; 7(10):7297-303. PubMed ID: 25400828
[TBL] [Abstract][Full Text] [Related]
4. [Immunohistochemical examination of MSH2, PMS2, MLH1, MSH6 compared with the analysis of microsatellite instability in colon adenocarcinoma].
Raskin GA; Ianus GA; Kornilov AV; Orlova RV; Petrov SV; Protasova AÉ; Pozharisskiĭ KM; Imianitov EN
Vopr Onkol; 2014; 60(2):47-50. PubMed ID: 24919261
[TBL] [Abstract][Full Text] [Related]
5. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.
Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D
J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419
[TBL] [Abstract][Full Text] [Related]
6. Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting.
Overbeek LI; Ligtenberg MJ; Willems RW; Hermens RP; Blokx WA; Dubois SV; van der Linden H; Meijer JW; Mlynek-Kersjes ML; Hoogerbrugge N; Hebeda KM; van Krieken JH
Am J Surg Pathol; 2008 Aug; 32(8):1246-51. PubMed ID: 18677806
[TBL] [Abstract][Full Text] [Related]
7. Evaluation and management of Lynch syndrome.
Boland CR
Clin Adv Hematol Oncol; 2007 Nov; 5(11):851,873. PubMed ID: 18185481
[No Abstract] [Full Text] [Related]
8. Mismatch Repair Protein Expression in Clear Cell Carcinoma of the Ovary: Incidence and Morphologic Associations in 109 Cases.
Bennett JA; Morales-Oyarvide V; Campbell S; Longacre TA; Oliva E
Am J Surg Pathol; 2016 May; 40(5):656-63. PubMed ID: 26813747
[TBL] [Abstract][Full Text] [Related]
9. Screening to detect Lynch syndrome and prevent hereditary cancers in relatives.
Haddow JE; Palomaki GE
J Med Screen; 2011; 18(4):167-8. PubMed ID: 22184732
[No Abstract] [Full Text] [Related]
10. Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center.
Moline J; Mahdi H; Yang B; Biscotti C; Roma AA; Heald B; Rose PG; Michener C; Eng C
Gynecol Oncol; 2013 Jul; 130(1):121-6. PubMed ID: 23612316
[TBL] [Abstract][Full Text] [Related]
11. The added value of PMS2 immunostaining in the diagnosis of hereditary nonpolyposis colorectal cancer.
Halvarsson B; Lindblom A; Rambech E; Lagerstedt K; Nilbert M
Fam Cancer; 2006; 5(4):353-8. PubMed ID: 16817031
[TBL] [Abstract][Full Text] [Related]
12. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients.
Hampel H; Frankel W; Panescu J; Lockman J; Sotamaa K; Fix D; Comeras I; La Jeunesse J; Nakagawa H; Westman JA; Prior TW; Clendenning M; Penzone P; Lombardi J; Dunn P; Cohn DE; Copeland L; Eaton L; Fowler J; Lewandowski G; Vaccarello L; Bell J; Reid G; de la Chapelle A
Cancer Res; 2006 Aug; 66(15):7810-7. PubMed ID: 16885385
[TBL] [Abstract][Full Text] [Related]
13. Tissue expression of MLH1, PMS2, MSH2, and MSH6 proteins and prognostic value of microsatellite instability in Wilms tumor: experience of 45 cases.
Diniz G; Aktas S; Cubuk C; Ortac R; Vergin C; Olgun N
Pediatr Hematol Oncol; 2013 May; 30(4):273-84. PubMed ID: 23570624
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of screening for Lynch syndrome among patients with colorectal cancer.
Hampel H; Frankel WL; Martin E; Arnold M; Khanduja K; Kuebler P; Clendenning M; Sotamaa K; Prior T; Westman JA; Panescu J; Fix D; Lockman J; LaJeunesse J; Comeras I; de la Chapelle A
J Clin Oncol; 2008 Dec; 26(35):5783-8. PubMed ID: 18809606
[TBL] [Abstract][Full Text] [Related]
15. Immunostaining in the context of loss mismatch repair function: interpretive confounders and cautionary tales!
Fadhil W; Field J; Cross G; Kaye P; Ilyas M
Histopathology; 2012 Sep; 61(3):522-5. PubMed ID: 22642480
[No Abstract] [Full Text] [Related]
16. Point: justification for Lynch syndrome screening among all patients with newly diagnosed colorectal cancer.
Hampel H
J Natl Compr Canc Netw; 2010 May; 8(5):597-601. PubMed ID: 20495086
[TBL] [Abstract][Full Text] [Related]
17. Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations.
Joost P; Therkildsen C; Dominguez-Valentin M; Jönsson M; Nilbert M
Urology; 2015 Dec; 86(6):1212-7. PubMed ID: 26385421
[TBL] [Abstract][Full Text] [Related]
18. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
[TBL] [Abstract][Full Text] [Related]
19. Mismatch repair gene deficiency and genetic anticipation in Lynch syndrome: myth or reality?
Ponti G; Ruini C; Tomasi A
Dis Colon Rectum; 2015 Jan; 58(1):141-2. PubMed ID: 25489705
[No Abstract] [Full Text] [Related]
20. Counterpoint: implementing population genetic screening for Lynch Syndrome among newly diagnosed colorectal cancer patients--will the ends justify the means?
Hall MJ
J Natl Compr Canc Netw; 2010 May; 8(5):606-11. PubMed ID: 20495087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
